Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Receivables: 2010-2025

Historic Receivables for Heron Therapeutics (HRTX) over the last 9 years, with Sep 2025 value amounting to $81.0 million.

  • Heron Therapeutics' Receivables rose 20.90% to $81.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $318.9 million, marking a year-over-year increase of 19.64%. This contributed to the annual value of $79.1 million for FY2024, which is 30.93% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Receivables is $81.0 million, which was up 1.40% from $79.9 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Receivables peaked at $81.0 million during Q3 2025, and registered a low of $35.7 million during Q4 2021.
  • Its 3-year average for Receivables is $70.7 million, with a median of $73.7 million in 2024.
  • Its Receivables has fluctuated over the past 5 years, first dropped by 15.27% in 2021, then surged by 90.29% in 2023.
  • Quarterly analysis of 5 years shows Heron Therapeutics' Receivables stood at $35.7 million in 2021, then skyrocketed by 62.95% to $58.2 million in 2022, then increased by 3.78% to $60.4 million in 2023, then skyrocketed by 30.93% to $79.1 million in 2024, then increased by 20.90% to $81.0 million in 2025.
  • Its Receivables was $81.0 million in Q3 2025, compared to $79.9 million in Q2 2025 and $78.7 million in Q1 2025.